Literature DB >> 9662124

Stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10) expression in developing human bone: potential roles in skeletal development.

S Bord1, A Horner, R M Hembry, J E Compston.   

Abstract

Stromelysin, a member of the matrix metalloproteinase family, demonstrates wide substrate specificity with the ability to degrade proteoglycan, fibronectin, laminin, casein, and the nonhelical region of collagen. The two forms of stromelysin (SL), types 1 (MMP-3) and 2 (MMP-10), share 82% sequence homology, but exhibit differences in cellular synthesis and inducibility by cytokines and growth factors in vitro. However, the distribution of the two isoforms in bone has not been reported. We investigated the presence of SL-1 and SL-2 in human osteophytic and neonatal rib bone using immunohistochemistry and, combined with a new method of in situ zymography, determined the activity of the immunolocalized stromelysins. Latent SL-1 was strongly expressed in the extracellular matrix in fibrous tissue surrounding areas of endochondral ossification in osteophytes, and adjacent to the periosteum of fetal rib bone. Active SL-1 expression was detected in osteocytes and the matrix surrounding osteocytic lacunae. SL-2 showed intense cell-associated staining at sites of resorption in areas of endochondral ossification and in resorptive cells at the chondro-osseous junction, which correlated with enzyme activity detected by zymography. Within the rib, active SL-2 expression was localized in chondrocytes of the growth plate, whereas only occasional SL-1 signal was evident. Vascular areas showed strong SL-2 staining with some proteolytic activity. SL-2, but not SL-1, was strongly expressed in osteoclasts and most mononuclear cells within the marrow. At sites of bone formation both isoforms were expressed by osteoblasts with SL-1 also present in osteoid. These results demonstrate, for the first time, the differential expression of SL-1 and SL-2 in developing human bone, indicating specific roles for the two isoforms. In situ zymography demonstrates that SL-2 is produced in an active form with associated degradation, whereas SL-1, in a matrix-bound proenzyme form, may act as a reservoir for later activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9662124     DOI: 10.1016/s8756-3282(98)00064-7

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  23 in total

Review 1.  Matrix remodeling during endochondral ossification.

Authors:  Nathalie Ortega; Danielle J Behonick; Zena Werb
Journal:  Trends Cell Biol       Date:  2004-02       Impact factor: 20.808

2.  Dual regulation of metalloproteinase expression in chondrocytes by Wnt-1-inducible signaling pathway protein 3/CCN6.

Authors:  Natasha Baker; Paul Sharpe; Kirsty Culley; Miguel Otero; Damon Bevan; Peter Newham; Wendy Barker; Kristen M Clements; Caroline J Langham; Mary B Goldring; Jelena Gavrilović
Journal:  Arthritis Rheum       Date:  2012-07

3.  Transcriptome-Wide Regulation of Key Developmental Pathways in the Mouse Neural Tube by Prenatal Alcohol Exposure.

Authors:  Karen E Boschen; Travis S Ptacek; Jeremy M Simon; Scott E Parnell
Journal:  Alcohol Clin Exp Res       Date:  2020-07-01       Impact factor: 3.455

4.  The effects of Acanthopanax senticosus extract on bone turnover and bone mineral density in Korean postmenopausal women.

Authors:  You-Cheol Hwang; In-Kyung Jeong; Kyu Jeung Ahn; Ho Yeon Chung
Journal:  J Bone Miner Metab       Date:  2009-05-20       Impact factor: 2.626

5.  Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex Multiplex technology.

Authors:  Kathryn M Thrailkill; Cindy S Moreau; Gael Cockrell; Pippa Simpson; Rajiv Goel; Paula North; John L Fowlkes; Robert C Bunn
Journal:  Clin Chem Lab Med       Date:  2005       Impact factor: 3.694

6.  IL-6 upregulates a disintegrin and metalloproteinase with thrombospondin motifs 2 (ADAMTS-2) in human osteosarcoma cells mediated by JNK pathway.

Authors:  Meltem Alper; Feray Kockar
Journal:  Mol Cell Biochem       Date:  2014-04-22       Impact factor: 3.396

7.  Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure.

Authors:  Jyotica Batra; Jessica Robinson; Alexei S Soares; Alan P Fields; Derek C Radisky; Evette S Radisky
Journal:  J Biol Chem       Date:  2012-03-16       Impact factor: 5.157

8.  Overexpression of matrix metalloproteinase-10 and matrix metalloproteinase-3 in human diabetic corneas: a possible mechanism of basement membrane and integrin alterations.

Authors:  M Saghizadeh; D J Brown; R Castellon; M Chwa; G H Huang; J Y Ljubimova; S Rosenberg; K S Spirin; R B Stolitenko; W Adachi; S Kinoshita; G Murphy; L J Windsor; M C Kenney; A V Ljubimov
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

9.  MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas.

Authors:  Jason H Gill; Ian G Kirwan; Jill M Seargent; Sandie W Martin; Sidiq Tijani; Vladimir A Anikin; Alan J Mearns; Michael C Bibby; Alan Anthoney; Paul M Loadman
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

10.  TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-kappaB.

Authors:  Y Ye; L M Pringle; A W Lau; D N Riquelme; H Wang; T Jiang; D Lev; A Welman; G A Blobel; A M Oliveira; M M Chou
Journal:  Oncogene       Date:  2010-04-26       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.